Vaklavas, Christos http://orcid.org/0000-0002-9919-2748
,
Roberts, Brian S.
Varley, Katherine E.
Lin, Nancy U.
Liu, Minetta C.
Rugo, Hope S.
Puhalla, Shannon
Nanda, Rita
Storniolo, Anna Maria
Carey, Lisa A.
Saleh, Mansoor N.
Li, Yufeng
Delossantos, Jennifer F.
Grizzle, William E.
LoBuglio, Albert F.
Myers, Richard M.
Forero-Torres, Andres
Funding for this research was provided by:
National Cancer Institute (P50CA089019)
Susan G. Komen (IIR13265422)
Article History
Received: 29 August 2019
Accepted: 6 February 2020
First Online: 18 February 2020
Ethics approval and consent to participate
: The protocol was reviewed and approved by each participating institution, and the study followed the Declaration of Helsinki and good clinical practice guidelines. All patients gave informed consent.
: Not applicable.
: C.V. consulting or advisory board: Daiichi-Sankyo, Genentech (unpaid); research funding (paid to the University of Alabama at Birmingham): Roche, Pfizer, Incyte, Novartis, Pharmacyclics, Tracon, Innocrin, H3 Biomedicine, Zymeworks. A.F.T received support from Genentech to conduct clinical and laboratory research (paid to the University of Alabama at Birmingham). A.F.T. is currently an employee of Seattle Genetics. N.U.L.—consulting or advisory board: Puma, Daiichi-Sankyo, Seattle Genetics, Genentech; research funding (paid to institution): Genentech, Pfizer, Novartis, Seattle Genetics, Array Biopharma. The remaining authors declare that they have no competing interests.